Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL-172154 · 1 trial · 3 indications
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-172154 | EXPERIMENTAL | Intravenous administration |
| Name | Type | Description |
|---|---|---|
| SL-172154 | DRUG | The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject must have a his...
Top 20 of 59 competitors
SL-172154 is an investigational small molecule being studied for the treatment of ovarian cancer. It is being developed by Shattuck Labs, Inc. for this oncology indication. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
SL-172154 is a SIRPα-Fc-CD40L fusion protein, meaning it targets both SIRPα and CD40L pathways. It is designed to modulate immune responses in the tumor microenvironment. This mechanism is being evaluated in the context of ovarian cancer treatment.
SL-172154 is being developed by Shattuck Labs, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol STTK. Shattuck Labs is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
SL-172154 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received orphan drug designation for its intended use in ovarian cancer. It is still in the early stages of clinical testing.
SL-172154 has one completed Phase 1 clinical trial, identified as NCT04406623. This trial enrolled 27 female participants aged 18 years and older in the United States. The study evaluated SL-172154 in patients with ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma.
Yes, SL-172154 is also known as SIRPα-Fc-CD40L. This name reflects its mechanism as a fusion protein combining SIRPα and CD40L components. The drug is being investigated under both names in clinical research contexts.